The U.S. Food and Drug Administration recently approved Auvelity as the first non-antipsychotic medication for treating agitation in patients with Alzheimer disease, marking a significant advancement in managing behavioral symptoms associated with dementia due to Alzheimer’s. This new option provides an alternative to traditional antipsychotic treatments.
Auvelity Offers New Option for Agitation in Alzheimer Disease
Auvelity received FDA approval after clinical trials demonstrated its safety and efficacy in reducing agitation episodes in adults with Alzheimer disease. Symptoms of agitation in these patients often include restlessness, irritability, and aggression, which contribute substantially to both patient distress and the caregiver burden. Prior to Auvelity, treatment primarily involved antipsychotic drugs that are not specifically approved for agitation in Alzheimer disease and carry risks of serious side effects.
Emergence of Disease-Modifying Therapies for Alzheimer Disease
Alongside Auvelity, the FDA approved several other drugs targeting different aspects of Alzheimer disease. Kisunla (donanemab-azbt) was authorized as an injectable treatment designed to slow disease progression in adults. Leqembi (lecanemab-irmb) obtained accelerated approval to target amyloid beta plaques, a hallmark of Alzheimer pathology, introducing a new disease-modifying therapy option.
Both Leqembi and Kisunla utilize monoclonal antibodies to reduce amyloid plaque buildup in the brain. Clinical studies indicated that patients on these therapies experienced a slowing in cognitive decline compared to those on standard care.
Additional Medication Approvals for Agitation in Alzheimer Disease
The FDA also granted supplemental approval for Rexulti (brexpiprazole) oral tablets to treat agitation related to dementia due to Alzheimer disease. Rexulti is an antipsychotic medication specifically approved for agitation symptoms, offering clinicians another regulated treatment choice, though its use requires caution given the known risks of antipsychotic drugs in elderly dementia patients.
Regulatory Advances Expand Alzheimer Disease Treatment Landscape
These approvals come after a long period of limited drug development in Alzheimer disease, which previously saw few new therapies approved. Aducanumab and lecanemab, both targeting amyloid accumulation, represented major breakthroughs after nearly two decades without new drug authorizations. The FDA also supports expanded access and compassionate use programs that allow patients with neurodegenerative conditions to receive investigational treatments, reflecting ongoing efforts to improve patient outcomes.
Collectively, these regulatory actions demonstrate progress in Alzheimer disease treatment across the United States, including regions such as Miami and South Florida, by broadening options for patients through both symptom management and disease-modifying therapies.
